Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr;12(4):e1259.
doi: 10.1002/iid3.1259.

Immunocompromised individuals are at increased risk of COVID-19 breakthrough infection, hospitalization, and death in the post-vaccination era: A systematic review

Jola Bytyci  1 , Yuxin Ying  1 , Lennard Y W Lee  2   3
Affiliations

Immunocompromised individuals are at increased risk of COVID-19 breakthrough infection, hospitalization, and death in the post-vaccination era: A systematic review

Jola Bytyci et al. Immun Inflamm Dis. 2024 Apr.

Abstract

Introduction: Immunocompromised individuals have been shown to mount a reduced response to vaccination, resulting in reduced vaccine effectiveness in this cohort. Therefore, in the postvaccination era, immunocompromised individuals remain at high risk of breakthrough infection and COVID-19 related hospitalization and death, which persist despite vaccination efforts. There has been a marked paucity of systematic reviews evaluating existing data describing the clinical measures of efficacy of COVID-19 vaccination, specifically in immunocompromised populations. In particular, there is a scarcity of comprehensive evaluations exploring breakthrough infections and severe COVID-19 in this patient population.

Methods: To address this gap, we conducted a systematic review which aimed to provide a summary of current clinical evidence of the effectiveness of COVID-19 vaccination in the immunocompromised population. Using PRISMA guidelines, we conducted a literature search on PubMed and the Cochrane database published between January 1, 2021 to September 1, 2022.

Results: Our findings demonstrated that despite vaccination, immunocompromised patients remained at high risk of new breakthrough COVID-19 infection and severe COVID-19 outcomes compared to the general population. We found increased average relative risk (RR) of breakthrough infections in the immunocompromised population, including patients with cancer (RR = 1.4), HIV (RR = 1.92), chronic kidney disease (RR = 2.26), immunodeficiency (RR = 2.55), and organ transplant recipients (RR = 6.94). These patients are also at greater risk for hospitalizations and death following COVID-19 breakthrough infection. We found that the RR of hospitalization and death in Cancer patients was 1.08 and 2.82, respectively.

Conclusion: This demonstrated that vaccination does not offer an adequate level of protection in these groups, necessitating further measures such as Evusheld and further boosters.

Keywords: SARS‐CoV‐2; cancer; severe COVID‐19 outcomes; vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flowchart.
See this image and copyright information in PMC

References

    1. Lee LYW, Cazier JB, Starkey T, et al. COVID‐19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21:1309‐1316. - PMC - PubMed
    1. Collaborative TO, et al. Changes in COVID‐19‐related mortality across key demographic and clinical subgroups: an observational cohort study using the OpenSAFELY platform on 18 million adults in England. medRxiv. 2022. 10.1101/2022.07.30.22278161 - DOI
    1. Turtle L, et al. Outcome of COVID‐19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP‐UK prospective cohort study. medRxiv. 2022. 10.1101/2022.08.08.22278576 - DOI - PMC - PubMed
    1. Wise J. Covid‐19: Evusheld is approved in UK for prophylaxis in immunocompromised people. BMJ. 2022;376:o722. - PubMed
    1. Lee ARYB, Wong SY, Chai LYA, et al. Efficacy of covid‐19 vaccines in immunocompromised patients: systematic review and meta‐analysis. BMJ. 2022;376:e068632. - PMC - PubMed

Publication types

Substances

Supplementary concepts